Amgen has unveiled clinical trial results for its next-generation weight loss injection MariTide, showing an average 30% body fat reduction over 6 months — significantly outperforming current GLP-1 medications.
How It Works
Unlike Ozempic and Wegovy which target GLP-1 receptors alone, MariTide simultaneously activates GLP-1 and blocks GIP receptors, creating a dual mechanism that accelerates fat burning while preserving muscle mass.
- Average weight loss: 30% of body fat in 6 months
- Muscle preservation: 95% of lean mass retained
- Dosing: once monthly (vs weekly for Ozempic)
- Side effects: nausea in 18% of patients (less than GLP-1s)
FDA fast-track designation has been granted with approval expected by Q1 2027.
